CMMB (Chemomab Therapeutics) Moat Score: 4/10 (As of Jun. 27, 2026)


CMMB Chemomab Therapeutics Ltd CMMB
34 GF Score
Price $1.59
View Full Analysis

What is Chemomab Therapeutics Moat Score?

Chemomab Therapeutics CMMB 34 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates CMMB with a GF Score™ of 34/100. Among 1,404 Biotechnology companies, Chemomab Therapeutics ranks better than 88.82% on this metric.

Chemomab Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Chemomab Therapeutics has Narrow Moat: Chemomab Therapeutics has a discernible but modest moat due to its focus on niche therapeutic areas and some valuable intellectual property. However, it lacks strong brand strength and significant market share, limiting its competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Chemomab Therapeutics might have Narrow Moat - Discernible but modest moat.

Chemomab Therapeutics  (NAS:CMMB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Chemomab Therapeutics Moat Score Related Terms

CMMB vs HCWB, MTVA, INTI: Moat Score Comparison

For the Biotechnology subindustry, Chemomab Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Moat Score falls into.


CMMB
34GF Score
Chemomab Therapeutics Ltd CMMB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Chemomab Therapeutics (CMMB) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Chemomab Therapeutics ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Chemomab Therapeutics' Moat Score too high?
Chemomab Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Chemomab Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Chemomab Therapeutics ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Moat Score compare to HCWB and MTVA?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #157 out of 1404 companies for Moat Score. This places Chemomab Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Chemomab Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemomab Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemomab Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for CMMB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price